These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30477373)

  • 21. Risk factors for drug-induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis.
    Pore SM; Shinde KB
    J Postgrad Med; 2014; 60(2):225-6. PubMed ID: 24823543
    [No Abstract]   [Full Text] [Related]  

  • 22. Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis.
    Pore SM; Shinde K
    J Postgrad Med; 2014; 60(1):90-2. PubMed ID: 24625953
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study.
    Sun Q; Zhang Q; Gu J; Sun WW; Wang P; Bai C; Xiao HP; Sha W
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):908-17. PubMed ID: 26935778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury.
    Monteiro TP; El-Jaick KB; Jeovanio-Silva AL; Brasil PE; Costa MJ; Rolla VC; de Castro L
    J Clin Pharm Ther; 2012 Dec; 37(6):712-8. PubMed ID: 22845549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comments on 'Risk factors for drug induced hepatitis with first-line antituberculosis drugs in hospitalized patients of pulmonary tuberculosis'.
    Animesh R
    J Postgrad Med; 2014; 60(2):224-5. PubMed ID: 24823542
    [No Abstract]   [Full Text] [Related]  

  • 26. [Incidence and outcome of anti-tuberculosis drug-induced hepatotoxicity in tuberculosis inpatients].
    Chen SX; Zhou L; Chen YZ; Pan HQ; Tang SW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Jul; 37(7):930-4. PubMed ID: 27453099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury.
    Devarbhavi H; Singh R; Patil M; Sheth K; Adarsh CK; Balaraju G
    J Gastroenterol Hepatol; 2013 Jan; 28(1):161-7. PubMed ID: 23020522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
    Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
    Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury.
    Udomsinprasert W; Chanhom N; Suvichapanich S; Wattanapokayakit S; Mahasirimongkol S; Chantratita W; Jittikoon J
    Sci Rep; 2020 Mar; 10(1):5628. PubMed ID: 32221362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased activities of daily living is a strong risk factor for liver injury by anti-tuberculosis drugs.
    Horita N; Miyazawa N; Yoshiyama T; Tsukahara T; Takahashi R; Tsukiji J; Kato H; Kaneko T; Ishigatsubo Y
    Respirology; 2013 Apr; 18(3):474-9. PubMed ID: 23127245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
    Zhao H; Wang Y; Zhang T; Wang Q; Xie W
    Med Sci Monit; 2020 Mar; 26():e920350. PubMed ID: 32145061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered expressions of circulating microRNAs 122 and 192 during antitubercular drug induced liver injury indicating their role as potential biomarkers.
    Bakshi S; Kaur M; Saini N; Mir AA; Duseja A; Sinha SK; Sharma S
    Hum Exp Toxicol; 2021 Sep; 40(9):1474-1484. PubMed ID: 33729026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
    JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
    [No Abstract]   [Full Text] [Related]  

  • 35. Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
    Trigo C; do Brasil PE; Costa MJ; de Castro L
    J Viral Hepat; 2016 Dec; 23(12):1027-1035. PubMed ID: 27624908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.
    Hwang SJ; Wu JC; Lee CN; Yen FS; Lu CL; Lin TP; Lee SD
    J Gastroenterol Hepatol; 1997 Jan; 12(1):87-91. PubMed ID: 9076631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tuberculous drug induced liver injury - Do we need to rethink?
    Pandey J; Madaan P; Saini L; Verma S
    Indian J Tuberc; 2020 Apr; 67(2):260-261. PubMed ID: 32553322
    [No Abstract]   [Full Text] [Related]  

  • 38. [Isoniazid-induced hepatic failure. Report of a case].
    Pereira RM; Tresoldi AT; Hessel G
    Arq Gastroenterol; 2000; 37(1):72-5. PubMed ID: 10962632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.
    Graham DJ; Drinkard CR; Shatin D
    Am J Gastroenterol; 2003 Jan; 98(1):175-9. PubMed ID: 12526954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.